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SafetyAbstract Objective: A continuous infusion of a single high dose of dobutamine was suggested as a
simple protocol of dobutamine stress echocardiography (DSE). The present study explores the
feasibility and safety of an accelerated DSE protocol in patients with calciﬁc moderate valvular
aortic stenosis undergoing DSE for evaluation of suspected coronary artery disease.
Methods: Eligible patients (n= 100) were prospectively enrolled. They were randomly assigned to
undergo either the accelerated (group A, 50 patients) or the conventional protocol (group B, 50
patients). Group A received a continuous infusion of 40 lg/kg/min ± 1–2 mg atropine. Patients
were monitored for adverse drug effects. Test duration was recorded. Patients with positive stress
results underwent coronary angiography (CA).
Results: Mean age of the study cohort was 62.29 ± 9.8 years, 62 (62%) being males. Mean
pressure gradient across the aortic valve was recorded (group A: 32.2 mmHg and group B:
31.16 mmHg, P< 0.05). Group B showed a longer mean test duration (17.9 ± 2.3 vs.
8.9 ± 1.9 min, P< 0.001) and higher mean weight-adjusted cumulative dobutamine dose
(385 ± 115 vs. 350 ± 110.24 lg/kg, P< 0.05). The two groups received a similar total dose of
atropine. Group A patients showed signiﬁcantly lower incidence of extra-systoles, non-sustained
ventricular tachycardia and severe hypotension (P< 0.05). CA results yielded almost similar
diagnostic outcomes in both groups.
Conclusion: In patients with calciﬁc moderate aortic stenosis undergoing DSE; adopting the
described accelerated protocol is associated with shorter test duration, lower weight-adjusted
cumulative dobutamine dose for target heart rate achievement and fewer adverse effects, while
maintaining a comparable diagnostic value.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Dobutamine stress echocardiography (DSE) is widely used for
the diagnosis of coronary artery disease (CAD). Data regard-
ing the diagnosis of CAD in patients with moderately elevated
maximal gradient across the stenosed aortic valve (AV) are
limited. However, the diagnostic value of DSE for the diagno-
sis of CAD in patients with stenosed AV is high.1 Safety of
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The most frequent side effects are hypotension and arrhyth-
mia.2 Currently, in patients with suspected or known CAD,
most laboratories use stepwise increments of dobutamine at
three-minute intervals, which had evolved from the commonly
used exercise treadmill protocols. However, steady-state dobu-
tamine levels during dobutamine infusion are not obtained for
up to ten minutes.3–5 Consequently, the full effect of any infu-
sion rate of dobutamine is not obtained before the dobutamine
dose had advanced to the next level6 and plasma dobutamine
concentrations increase rapidly and non-linearly during the
test.7–9 Shortening the time of infusion of dobutamine would
increase the feasibility and the cost effectiveness of DSE.10
Therefore, a continuous infusion of a single high dose of
dobutamine has been suggested as a simple and effective pro-
tocol of DSE.7,11 It is worth mentioning that an ‘‘accelerated’’
dipyridamole infusion protocol had been already used12 and
validated in a large study.10
The current study prospectively sought to explore the feasi-
bility and safety of infusion of a ﬁxed high dose of dobutamine
i.e. accelerated DSE protocol in achieving the target heart rate
compared to the conventional DSE protocol, in a series of
patients suffering from calciﬁc moderate valvular aortic steno-
sis, being evaluated for suspected CAD.
2. Materials and methods
2.1. Study design and data collection
A total number of 100 consecutive patients suffering from cal-
ciﬁc moderate valvular aortic stenosis were prospectively
enrolled in the present study. They were referred to the stress
echocardiography lab in the Cardiology department of Ain
Shams University (Cairo, Egypt) in the period between
February 2011 and August 2013. Patients were considered eli-
gible for inclusion if they exhibit normal resting left ventricle
ejection fraction (LVEF%) and suffer from symptoms sugges-
tive of myocardial ischemia, requiring evaluation by DSE.
Exclusion criteria included; prior history of unstable angina
or myocardial infarction (MI), previous percutaneous coro-
nary intervention (PCI) or coronary artery bypass graft
(CABG) surgery, other etiologies of aortic stenosis or signiﬁ-
cant aortic regurgitation, presence of other signiﬁcant valvular
disease, congenital heart disease or any myocardial disease
apart from ischemia. Also, patients with contraindications to
dobutamine infusion (for example; with a history of complex
ventricular arrhythmias or uncontrolled hypertension with
blood pressure >180/110 mmHg), with contraindications to
atropine intake (for example; with a history of narrow-angle
glaucoma or obstructive uropathy) and patients with limited
life expectancy due to coexistent disease (for example; malig-
nancy), were excluded. After enrollment, patients were ran-
domly assigned in 1:1 fashion to undergo either; accelerated
DSE protocol (group A) or conventional DSE protocol (group
B) according to a computer-generated random series of num-
bers. Randomization was performed by block randomization
(blocks of 10 patients). All included patients were subjected
to detailed history taking including drug-intake, continuous
electrocardiogram (ECG) monitoring, in addition to baseline
transthoracic echocardiogram (TTE) assessment before stress
testing. All included patients stopped beta blocker and calciumantagonist therapies 48 h before stress testing, while nitrate
therapy was stopped 24 h before it. Before inclusion, informed
written consent was obtained from each patient and the study
protocol was reviewed and approved by our local institutional
human research committee; as it conforms to the ethical guide-
lines of the 1975 Declaration of Helsinki, as revised in 2008.
2.2. Deﬁnition of risk factors of coronary artery disease
The presence of hypertension was deﬁned as systolic blood pres-
sureP140 mmHg and/or diastolic blood pressureP90 mmHg,
previously recorded by repeated non-invasive ofﬁce measure-
ments, which led to life-style modiﬁcation and/or intake of anti-
hypertensive drug therapy.13 The presence of diabetes mellitus
was deﬁned as fasting plasma glucose P126 mg/dl and/or 2 h
post-glucose load P200 mg/dl, or speciﬁc anti-diabetic drug
therapy intake.14 Dyslipidemia was deﬁned as LDL cholesterol
>100 mg/dl, and/or serum triglycerides >150 mg/dl, and/or
HDL cholesterol <40 mg/dl (<50 mg/dl in women).15
2.3. Baseline echocardiographic assessment
Assessment of regional and global LV systolic functions was
performed in all patients by TTE using a General Electric
Vivid 7 cardiac ultrasound machine (General Electric, Horten,
Norway), equipped with harmonic imaging capabilities. A
2.5 MHz phased array probe was used to obtain standard
2D, M-mode and Doppler images. Patients were examined in
the left lateral recumbent position using standard parasternal
and apical views. Images were digitized in cine-loop format,
and saved for subsequent playback and analysis. Views were
analyzed by a single echocardiographer blinded to the study
protocol, employing the software program of the echocardiog-
raphy machine. All patients suffered from calciﬁc moderate
valvular aortic stenosis deﬁned echocardiographically by
having aortic valve area of 1–1.5 cm2 (measured using continu-
ity equation) and recorded mean pressure gradient (PG) of
25–40 mmHg (across the valve).16 Regional wall motion was
assessed according to the standard 17-segment model as rec-
ommended by the American Society of Echocardiography.17
That was achieved through visual assessment for each segment
individually, considering both endocardial excursion and sys-
tolic thickening. Each segment was graded according to the
semi-quantitative scoring system described by Knudsen et al.18
Segments with poorly-deﬁned endocardial borders for 50% or
more of their length were considered non-visualized and
assigned a score of 0.19 Wall thickening was assessed at a dis-
tance of at least 1 cm from the adjacent segment, to minimize
the effect of tethering.20
2.4. Dobutamine stress echocardiography protocols
Once eligible, patients were randomly assigned to undergo one
of the following two DSE protocols:
2.4.1. Accelerated DSE protocol (group A, 50 patients)
Dobutamine (Dobutamine MYLAN, MYLAN S.A.S,
France) was administered by intravenous (IV) infusion using
a high ﬁxed dose from the start (40 lg/kg/min). Infusion
duration was assigned to be 10 min. In patients not achieving
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of 1.0 mg of IV atropine was administered, followed by
another similar dose after 1 min, if needed. Test was termi-
nated upon reaching any of the test end-points.
2.4.2. Conventional DSE protocol (group B, 50 patients)
Dobutamine was administered by IV infusion starting at a
dose of 5 lg/kg/min and raised incrementally every three
minutes up to a maximum of 40 lg/kg/min or until a study
end-point was reached. In patients not achieving 85% of their
APMHR at the end of the ﬁnal stage, IV atropine was
administered in 0.25–0.5 mg increments at one-minute
intervals up to a maximum dose of 2.0 mg, while dobutamine
infusion was continued.
2.5. Test termination end-points
End-points for terminating the test included: attainment of the
maximum dose of dobutamine and/or atropine; achievement
of target heart rate (>85% of APMHR); echocardiographic
detection of wall motion abnormality not present at baseline
or worsening of previously existing wall motion abnormality;
symptoms judged to be unacceptable by the attending
cardiologist; serious arrhythmia detected by ECG monitoring,
ST segment elevation >0.1 mV at 80 ms from the J point,
systolic blood pressure >200 mmHg or diastolic blood pres-
sure >110 mmHg or a decrease in systolic blood pressure
>30 mmHg from the baseline.21 Standard views were recorded
at the baseline, at the end of each stage of dobutamine infu-
sion, as well as during recovery. Visual assessment of wall
motion and systolic thickening was performed as mentioned
before. The test was considered positive upon detecting wall
motion abnormality not present at the baseline, or worsening of
previously existing wall motion abnormality in two contagious
LV segments belonging to the same blood supply territory.
2.6. Patients’ monitoring
All patients had continuous heart rate, ECG and pulse oxim-
etry monitoring. All patients were subjected to heart rate,
non-invasive blood pressure and 12-lead ECG recordings at
baseline, every three minutes and during recovery. Patients
were asked at the end of the test regarding any symptoms or
adverse drug reactions. Test duration was recorded from the
onset of dobutamine infusion, till the end of the recovery
period. The point of time or the dose of dobutamine infusion
at which the test was terminated was recorded for each patient
in group A and group B, respectively. Moreover, the amount
of administered IV atropine was quantiﬁed for each patient.
2.7. Coronary angiography
All patients with positive DSE test results (in both groups)
underwent coronary angiography (femoral artery access using
Seldinger’s technique) within 2 weeks after stress testing.
Subsequently, coronary revascularization modalities were indi-
vidually tailored. Coronary angiographic data were interpreted
by an independent interventionalist, blinded to the results of
DSE test. Number of patients showing signiﬁcant coronary
stenosis (epicardial vessels of at least 2.5 mm diameter showingP70% diameter reduction) was recorded in both groups in
order to detect the positive predictive value (PPV) of each test
protocol.
2.8. Statistics
All continuous variables were statistically described in terms of
mean ± standard deviation (±SD). Categorical variables
were described with absolute and relative (percentage) frequen-
cies. Comparison of continuous variables between the study
groups was done using Student t-test. For comparing categor-
ical data, Pearson Chi square and Fisher exact tests were
performed. P values were used to describe signiﬁcance. All
statistical calculations were done using Statistical Package
for Social Sciences (SPSS for Windows) software (version
15.0, SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Baseline clinical characteristics
A total of 100 consecutive patients suffering from calciﬁc mod-
erate valvular aortic stenosis were prospectively enrolled in the
current study, which comprises 50 patients randomly assigned
to undergo the acceleratedDSE protocol (groupA), and 50 oth-
ers randomly assigned to undergo the conventional DSE proto-
col (group B). The mean age of the whole study cohort was
62.29 ± 9.8 years, 62 (62%) being male patients. The two
groups were matched regarding age, gender, risk factors of
CADand resting LVEF%.Table 1 shows baseline clinical char-
acteristics of the two study groups. No statistically signiﬁcant
difference was recorded between both groups concerning aortic
valve area and mean PG across AV both at rest and at peak
stress. Moreover, there was no recorded signiﬁcant rise in mean
PG across AV in both groups. These data are shown in Table 2.
3.2. Test protocol data
Patients belonging to group B had longer mean test duration
(17.9 ± 2.3 min vs. 8.9 ± 1.9 min, P< 0.001). All patients
achieved their target heart rate. Accelerated dobutamine infu-
sion offered a rapid increase in heart rate (13.7 ±5.2 vs. 6.3
±2.3 beats/min, P< 0.001). Regarding group B, ﬁve (10%)
patients achieved it at a dobutamine infusion rate of
30 lg/kg/min, while the remaining 45 (90%) patients achieved
it at a dobutamine infusion rate of 40 lg/kg/min ± IV atro-
pine. Meanwhile, in group A, 40 (80%) patients achieved their
target heart rate before the end of the assigned duration (ten
minutes) of dobutamine ﬁxed dose infusion (40 lg/kg/min), 7
(14%) patients achieved it after receiving 1.0 mg of IV atropine
and 3 (6%) patients achieved it after receiving 2.0 mg of IV
atropine. The mean weight-adjusted cumulative dose of dobu-
tamine used was recorded to be 350 ± 110.24 lg/kg among
group A patients, while it was recorded to be 385 ± 115 lg/kg
among group B (P< 0.05). No signiﬁcant difference was seen
between both groups regarding mean IV atropine dose admin-
istered. Analysis of intra-observer variability revealed a close
correlation between repeated measurements of regional wall
motion by the single operator, with a correlation coefﬁcient
r= 0.94.
Table 1 Baseline characteristics of the two study groups.
Variable Group A (No. = 50) Group B (No. = 50) *P value
Age (years) 63.4 ± 9.4 61.18 ± 10.2 >0.05
Males 30 (60) 32 (64) >0.05
Diabetes mellitus 27 (54) 25 (50) >0.05
Hypertension 29 (58) 30 (60) >0.05
Dyslipidemia 18 (36) 16 (32) >0.05
Smoking 14 (28) 12 (24) >0.05
Family history of CAD 7 (14) 8 (16) >0.05
CAD: coronary artery disease.
All variables, except age (mean ± SD) are presented as number (percentage).
P value >0.05= non-signiﬁcant.
* Student t-test and Pearson Chi-Square test.
Table 2 Echocardiographic data of the two study groups at rest and at peak stress.
Variable Group A (No. = 50) Group B (No. = 50) *P value
At rest LV EF (%) 55.5 ± 3.4 57 ± 3.2 >0.05
Mean PG across AV (mmHg) 32.2 ± 2.5 31.16 ± 3.9 >0.05
AV area (cm2) 1.33 ± 0.14 1.34 ± 0.12 >0.05
At peak stress LV EF (%) 50.3 ± 4.6 51.4 ± 5.9 >0.05
Mean PG across AV (mmHg) 31.6 ± 3.3 31.2 ± 4.3 >0.05
AV area (cm2) 1.33 ± 0.16 1.34 ± 0.13 >0.05
LV EF: left ventricle ejection fraction, PG: pressure gradient, AV: aortic valve.
All variables are presented as mean ± SD.
P value >0.05= non-signiﬁcant.
* Student t-test.
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Table 3 shows hemodynamic data recorded at rest and peak
stress (point of time at which the test was terminated due to
reaching any of the test end-points). No signiﬁcant difference
was recorded regarding mean heart rate, systolic and diastolic
blood pressure at baseline and at peak stress upon comparing
both groups.3.4. Safety of DSE protocols
The conventional DSE protocol revealed positive results for
coronary ischemia in 43 (86%) patients and negative results
in seven (14%) patients. The accelerated DSE protocol
showed positive results in 44 (88%) patients and negative
results in six (12%) patients. Reported complications fromTable 3 Hemodynamic data of the two study groups at rest and a
Variable Group A
At rest Systolic BP (mmHg) 127.4 ± 5
Diastolic BP (mmHg) 78.3 ± 5
Heart rate (bpm) 75.3 ± 4
At peak stress Systolic BP (mmHg) 150 ± 8
Diastolic BP (mmHg) 95.4 ± 6
Heart rate (bpm) 140 ± 7
BP: blood pressure, bpm: beat per minute.
All variables are presented as mean ± SD.
P value >0.05= non-signiﬁcant.
* Student t-test.the two DSE test protocols are summarized in Table 4. Mild
hypotension was deﬁned by a drop in systolic and/or diastolic
blood pressure by 620 mmHg, while severe hypotension was
deﬁned by a drop in systolic and/or diastolic blood pressure
by >20 mmHg. Hypertension was deﬁned by an increase in
systolic and/or diastolic blood pressure by >20 mmHg.
Patients belonging to group B showed a statistically signiﬁ-
cant higher incidence of ventricular extra-systoles, atrial
extra-systoles, non-sustained ventricular tachycardia, nausea,
headache and severe hypotension (P< 0.05). The same
group of patients showed higher incidence of atrial ﬁbrilla-
tion (Af), supraventricular tachycardia (SVT), symptomatic
bradycardia, chest pain and hypertension, yet did not reach
statistical signiﬁcance. There were no recorded cases of
sustained ventricular tachycardia, ventricular ﬁbrillation,
syncope or death in both groups, during or immediately after
the test.t peak stress.
(No. = 50) Group B (No. = 50) *P value
.2 126 ± 6 >0.05
.3 77.4 ± 6.7 >0.05
.3 78.36 ± 5.8 >0.05
.4 153.4 ± 9.2 >0.05
.4 97.5 ± 8.9 >0.05
.2 139.18 ± 8.3 >0.05
Table 4 Adverse outcomes among the two study groups.
Variable Group A (No. = 50) Group B (No. = 50) *P value
Arrhythmias Ventricular extrasystoles 4 (8) 15 (30) <0.05
Atrial extrasystoles 4 (8) 10 (20) <0.05
Atrial ﬁbrillation 0 (0) 3 (6) >0.05
Non sustained VT 0 (0) 5 (10) <0.05
Sustained VT 0 (0) 0 (0) –
SVT 0 (0) 2 (4) >0.05
Vf 0 (0) 0 (0) –
Bradycardia 1 (2) 4 (8) >0.05
Blood pressure Hypertension 2 (4) 5 (10) >0.05
Mild hypotension 3 (6) 7 (14) >0.05
Severe hypotension 1 (2) 6 (12) <0.05
General Chest pain 5 (10) 9 (18) >0.05
Nausea 4 (8) 12 (24) <0.05
Headache 1 (2) 6 (12) <0.05
VT: ventricular tachycardia, SVT: supraventricular tachycardia, Vf: ventricular ﬁbrillation.
All variables are presented as number (percentage).
P value >0.05= non-signiﬁcant.
P value <0.05= signiﬁcant.
* Pearson Chi-Square and Fisher exact tests.
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All patients with positive stress test results underwent coronary
angiography. Regarding the conventional DSE protocol, 36
patients showed angiographically signiﬁcant coronary stenosis
with a PPV of 83.7%. Meanwhile, 37 patients belonging
to accelerated DSE protocol group; showed signiﬁcant
coronary stenosis, mounting to a comparable PPV i.e. 84%
(P value >0.05).4. Discussion
Currently, DSE is widely approved for detection of CAD 22,
for risk stratiﬁcation after MI23 and for prediction of peri-
operative and late cardiac events in patients scheduled for
major surgery.24 However, in addition to being time consum-
ing, DSE had often been limited by patient intolerance; chieﬂy
related to drug adverse effects and test duration.25 Further-
more, heart rate response might be inadequate in elderly
patients and in patients receiving beta-blocker therapy.26 In
this case, larger doses of dobutamine and longer test durations
are needed, besides the addition of atropine to achieve the tar-
get heart rate.27,28 In turn, this would further increase patients’
intolerance. The author tested the hypothesis that administra-
tion of a high ﬁxed dose of dobutamine during DSE would
reduce dobutamine weight-adjusted cumulative dose and test
duration, and consequently improve tolerance of patients suf-
fering from moderate aortic stenosis, being subjected to DSE.
Moreover, this protocol can be adopted yielding a ﬁnal diag-
nostic outcome that is comparable to that obtained using the
conventional protocol.
4.1. Mechanisms of drug action
At low doses (up to 10 lg/kg/min), dobutamine induces a
marked inotropic effect, probably mediated by a combined
beta 1 and alpha 1 adrenoreceptor stimulation, augmenting
myocardial contractility without a signiﬁcant increase in heartrate.29 At higher doses of dobutamine infusion (20–40 lg/kg/
min), heart rate progressively increases through its action on
beta 2 adrenoreceptors. Systemic blood pressure modestly
increases as a result of an increase of the cardiac output, and
a decrease of the systemic vascular resistance; the alpha 1 adre-
noreceptor-mediated vasoconstriction is balanced by the beta 2
adrenoreceptor-mediated vasodilator effect. Consequent upon
these hemodynamic changes; myocardial oxygen demand
increases. Yet, in myocardial segments supplied by a coronary
artery with signiﬁcant stenosis, this increased demand cannot
be met with a parallel increase of myocardial blood ﬂow.
Hence, regional myocardial ischemia develops, and manifests
as regional wall motion abnormalities; detected by 2D echo-
cardiography. Atropine, instead, acts as reversible competitive
antagonist to acetylcholine action at muscarinic receptors in
the sino-atrial node, resulting in a positive chronotropic effect.
Indirectly, an inotropic effect would also be expected through
the force–frequency relationship; probably mediated by increased
availability of cytosolic calcium for actin–myosin interaction.30
4.2. Consequences of accelerated dobutamine infusion
The current study results showed that accelerated dobutamine
IV infusion signiﬁcantly decreased the test duration by about
50%, yielding almost similar percentage of positive results sug-
gesting myocardial ischemia, when compared against the con-
ventional DSE protocol. Also, this was achieved using a lower
weight-adjusted cumulative dobutamine dose, hence, yielding a
similar diagnostic outcome at a lower level of myocardial
ischemia. This adds to the safety proﬁle of the accelerated pro-
tocol. This might be due to modest increase of coronary blood
ﬂow with higher doses of dobutamine infusion; balancing myo-
cardial oxygen demand and delaying the appearance of myo-
cardial wall motion abnormalities. It is worth mentioning
that mean PG across AV was recorded to be almost similar
in both groups at rest and at peak dose of dobutamine infusion
with no signiﬁcant rise. This is probably due to a large number
of patients showing positive results suggesting myocardial
ischemia. Effect of increased heart rate is balanced by
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effect on the mean pressure gradient across the AV.
4.3. Safety of accelerated DSE protocol
Although, an almost similar percentage of patients showed
positive results for myocardial ischemia in both groups,
patients undergoing the conventional DSE protocol showed
a higher incidence of adverse effects including arrhythmias;
pointing to the arrhythmogenic potential of higher doses of
dobutamine.21 Interestingly, all episodes of non-sustained ven-
tricular tachycardia were recorded in the conventional DSE
group. Furthermore, they were all recorded in the recovery
period. This highlights the importance of this period that
requires continuous monitoring.
4.4. Comparison with other studies
Previous studies had reported the feasibility, tolerability and
safety of using the accelerated DSE protocols.7,31–33 Burger
et al. reported a signiﬁcant decrease in test protocol time and
weight-adjusted cumulative dobutamine dose upon adopting
the use of the accelerated protocol.7 Lu et al. also reported a
favorable safety proﬁle upon testing accelerated DSE proto-
col.31 However, their study protocol did not include a conven-
tional DSE arm and about 30% of the included patients did
not reach their APMHR. This might be explained by lower
IV atropine dose used per patient in comparison with the pres-
ent study. Most of the previous studies addressing the safety
issue of adopting the accelerated DSE protocol did not demon-
strate a signiﬁcant decline in the incidence of adverse drug
effects in comparison to the conventional DSE protocol. How-
ever, the present study demonstrated it signiﬁcantly. This
might be due to the higher number of patients showing positive
results for ischemia in the current study. Moreover, the
selected population in the present study is considered to be rel-
atively risky for adverse effects of dobutamine and it seemed
that they beneﬁted more from the accelerated protocol. To
the best of the author’s knowledge, the current study presents
the ﬁrst original research work evaluating the feasibility and
safety of using the described accelerated DSE protocol in eval-
uation of suspected CAD in patients with valvular aortic ste-
nosis. Finally, the fairly high rates of positive test results in
the conventional DSE group (86%) and accelerated DSE
group (88%) are more or less in agreement with the sensitivity
rates reported in validated articles in the literature34,35 which
described a sensitivity range of 74–86%.
4.5. Clinical implications
Patients with moderate valvular aortic stenosis might suffer
from a wide range of symptoms including exertional shortness
of breath, angina, dizziness or even, syncope. This population
of patients is much more susceptible to procedural complica-
tions of DSE protocols, primarily due to adverse drug reac-
tions (dobutamine and atropine). The performance of DSE
with a signiﬁcantly lower cumulative dose of dobutamine,
shorter test duration, with almost the same total dose of atro-
pine and with an essentially lower side-effect proﬁle, would be
an appealing option. All these advantages were clearly offered
by the accelerated DSE protocol, as shown in the presentstudy. Generally speaking, owing to its time-saving advantage,
the accelerated protocol could be of special importance in busy
stress echocardiography labs receiving a large number of
patients regularly. Hence, at least from the ‘safety’ point of
view, the author hypothesizes that adopting the accelerated
DSE protocol as the protocol of choice in patients with calciﬁc
moderate valvular aortic stenosis undergoing DSE for evalua-
tion of suspected CAD, should be encouraged.
4.6. Limitations of the study
The data presented in our study only apply for patients deﬁned
by inclusion and exclusion criteria. This is a single-center study
with a relatively small sample size of the cohort, a fact that
makes it difﬁcult to generalize our results to all patients with
aortic stenosis, undergoing DSE. This study included patients
with calciﬁc moderate valvular aortic stenosis. Other studies
are needed to evaluate patients with more severe valvular aor-
tic stenosis of other etiologies for the same purpose. Further-
more, test duration was calculated from the onset of
dobutamine infusion till the end of the recovery time, which
might be difﬁcult to demarcate in some cases. However, being
subjective in nature, it is difﬁcult to delineate precisely the end
of recovery time. Another limitation is lack of quantitative
methods of measuring systolic LV wall thickening. Instead,
the echocardiographer adopted visual assessment only.
Finally, the diagnostic accuracy of the two protocols of stress
testing was compared in terms of positive predictive value
only, since patients with negative stress test results did not
undergo coronary angiography. Further studies comparing
sensitivity, speciﬁcity and negative predictive value of both
protocols are needed.
4.7. Conclusion
In patients suffering from calciﬁc moderate valvular aortic ste-
nosis undergoing DSE; adopting the described accelerated pro-
tocol is associated with shorter test duration, lower weight-
adjusted cumulative dobutamine dose for target heart rate
achievement and consequently fewer adverse effects. Further-
more, these advantages could be obtained, while maintaining
a diagnostic value for CAD that is comparable to that
obtained by the conventional DSE protocol.
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